Anavex life sciences announces issuance of new u.s. patent expanding anavex®2-73 (blarcamesine) intellectual property portfolio for the treatment of hypertension

New york, may 01, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, announced today it was granted a new u.s. patent no. 11,622,955 entitled “sigma-1 receptor agonist systolic blood pressure therapy,” from the united states patent and trademark office (uspto), expanding anavex's coverage of treatment methods for anavex®2-73 (blarcamesine), to the treatment of systolic hypertension, or lowering systolic blood pressure.
AVXL Ratings Summary
AVXL Quant Ranking